BioLineRx Secures $5.6 Million via Royalty Monetization of APHEXDA
BioLineRx (NASDAQ: BLRX) has entered into an agreement with Soleus Capital Management to sell its 14.4% royalty interest in future net sales of APHEXDA for a one-time payment of $5.6 million. This non-dilutive financing allows the company to unlock immediate value from its existing license agreement with Ayrmid Pharma while retaining rights to potential commercial milestone payments. The proceeds are earmarked to support the clinical development of GLIX1, specifically its ongoing Phase 1/2a trial for glioblastoma and other solid tumors. Additionally, the funds will be used for working capital and a partial loan repayment to BlackRock EMEA Venture and Growth Lending, which will eliminate the company's $4 million minimum cash balance requirement.

Tickers: $BLRX
Topics: Biotechnology Clinical Development Non-dilutive Financing Royalty Sale